Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus XERAVA.
MYCHEL vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
Adults: 200 mg orally twice daily for 14 days.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic